FDA clears Molecular Designs’ multiplex test for flu and RSV

The test identifies and differentiates influenza A, influenza B, and respiratory syncytial virus RNA from anterior nasal swabs.

The US Food and Drug Administration (FDA) has cleared Molecular Designs’ SimplicityDx FluA/FluB/RSV panel, marking the company’s first cleared diagnostic assay.

The multiplex real-time reverse transcription polymerase chain reaction (RT-PCR) test identifies and differentiates influenza A, influenza B, and respiratory syncytial virus (RSV) RNA from anterior nasal swabs taken from individuals displaying symptoms of respiratory tract infection.

Sign up for Blog Updates